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Abstract
Immunohistochemistry (IHC) is a useful technique for the localization and semiquanti-
fication of protein expression within tissues. Adult human intervertebral disc (IVD) tissues
contain a large amount of auto-fluorescence which often makes immunofluorescence tech-
niques inappropriate on tissue samples but can be applied to isolated cell samples. Thus,
IHC remains one of, if not the most common application for protein detection within IVD
tissue. Immunostaining localizes antigen expression through specific epitope-antibody inter-
actions. Within the field of IVD research, IHC is commonly used on fresh frozen and paraf-
fin embedded tissues to elucidate the expression of antigens. Here, we discuss the
principles of IHC applied to formalin fixed paraffin embedded IVD tissue and supply opti-
mized protocols for antibodies usedwithin our group to guide researchwithin the IVD field.
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1 | INTRODUCTION
Immunohistochemistry (IHC) is a widely used technique by which target
antigens in tissue can be detected using specific antibodies. Primary
antibodies are applied to tissue sections which specifically bind to the
target antigen. Application of a secondary antibody directed against a
species-specific portion of the primary antibody is then applied. Second-
ary antibodies are conjugated, often to a fluorophore, enzyme or biotin,
thus allowing the detection and localization of the bound primary anti-
body. The method of detection used in this protocol utilizes a biotin
conjugated secondary antibody which enables an amplification step
using the ability of streptavidin to bind to four biotin molecules,1 this
enables amplification of the signal detected utilizing horseradish peroxi-
dase enzyme (HRP) conjugated to streptavidin-biotin complex.1 This
enzyme then converts the substrate, 3,30-diaminobenzidine
tetrahydrochloride (DAB), into a permanent brown precipitate on the
tissue (Figure 1). Counterstaining with hematoxylin allows for the deter-
mination of cellular localization and semiquantification of immuno-
positive (Figure 2, brown cellular staining) and immuno-negative cells
(Figure 2, purple/blue stained cell nuclei) (Table 1: IHC protocol). This
article aims to provide an overview of the principles of IHC and a clear
methodology for performing IHC, for a wide range of antibodies, on for-
malin fixed paraffin embedded (FFPE) sections of intervertebral disc
(IVD) tissue previously optimized by our research group.
2 | TISSUE PREPARATION
2.1 | Fixation
IHC can be performed on either frozen or FFPE tissue sections, typi-
cally FFPE samples are preferred for analysis of IVD tissue as thisAbbie Binch and Joseph Snuggs authors contributed equally to this article.
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enables long term storage of samples and improved morphological
maintenance during sectioning of particularly large tissue samples.
Following fixation in 10% w/v formalin or 4% (w/v) paraformalde-
hyde (all reagent suppliers and product codes listed in Table 2). It is
essential to ensure appropriate fixation; uneven fixation will result
in unreliable IHC staining and lead to difficulties in troubleshooting.
Over fixation may lead to brittle tissue sections. During fixation it is
important to ensure sufficient volume of fixative to sample with a
recommended 50:1 ratio of fixative to tissue sample.2 Small frag-
ments of disc tissue obtained from surgery such as discectomy, can
be fixed within 48 hours while large whole IVDs should be fixed for
a week to ensure complete fixation. For large samples where 50:1
ratio of fixative is not practical, the fixative should be changed every
48 hours, until fixative remains clear.
2.2 | Decalcification
If vertebral bone is included with the IVD sample such as cadaveric
discs, a form of decalcification may be required. Decalcification of
bone can be achieved using many different reagents that require vary-
ing lengths of time to fully decalcify specimens. Neutral 20% (w/v)
EDTA (pH 7) requires a longer decalcification time but causes little tis-
sue damage, whereas acidic decalcification acts rapidly but exceeding
the end-point will lead to extensive tissue damage and a loss of IHC
staining intensity and thus EDTA decalcification is recommended.3
Complete decalcification should be confirmed by X-ray analysis prior
to embedding into paraffin wax. Decalcification time should be opti-
mized according to the size of the tissue sample.
2.3 | Embedding and sectioning
Following paraffin embedding thin sections (normally 4 μm thick) are
prepared on a microtome and floated on a water bath prior to mount-
ing onto positively charged slides (it is important to use thin sections
to ensure antibody penetration). When mounting, extra care should
be taken to avoid tissue folding. Where folds are generated these
areas of tissue should not be included in downstream analysis as trap-
ping of reagents may lead to nonspecific staining. Following mounting
onto slides, sections should be dried for a minimum of 1 week to pre-
vent detachment during staining (longer if heat antigen retrieval
methods are to be used).
3 | DEWAXING AND REHYDRATION
Tissue sections embedded in paraffin wax should be deparaffinized in
xylene or a xylene substitute such as Sub-X or Histoclear (Leica) prior to
removal of xylene in alcohol (Industrial methylated spirts used here).
F IGURE 1 Principle of Immunohistochemistry. Target antigens are detected by the application of specific primary antibodies, followed by the
addition of a biotin conjugated secondary antibody which recognizes a specific sequence on the primary antibody. Localisation of bound biotinylated
secondary antibody is detected by the addition of streptavidin HRP labeled ABC solution which binds to the biotin on the secondary. Enzymatic color
changes occur when DAB reacts with the HRP bound to the secondary antibody, thus resulting in the detection of the target antigen
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4 | BLOCKING ENDOGENOUS
PEROXIDASES
When enzymatic detection methods are utilized, it is essential that
endogenous enzymes are removed from tissues to prevent non-
specific staining when the chromogen is added. The enzyme used in
this protocol is HRP and thus endogenous peroxidases are exhausted
by immersing slides into 3% (v/v) hydrogen peroxide (Sigma, UK) in
ethanol (Fisher Scientific, UK) containing 0.06% (v/v) HCl for
30 minutes. Sections are then washed once in deionized water and
then twice in Tris-Buffered Saline (TBS: 20 mM Tris [Fisher Scientific,
UK]; 150 mM NaCl [Fisher Scientific, UK]; pH 7.5) which ensures sec-
tions are fully rehydrated prior to further steps.
5 | ANTIGEN RETRIEVAL
As formalin fixation results in crosslinking of proteins this can lead to
antigen masking. Furthermore, antigens can be hidden by extracellular
matrix components or cellular membranes in the case of intracellular
proteins. Therefore in many cases it may be necessary to unmask the
antigen by performing an antigen-retrieval technique.4 There are mul-
tiple antigen retrieval methods available which can be divided into
chemical, enzymatic and heat retrieval methods.5-7 Antigen retrieval
methods are determined for each individual antigen and antibody; no
antigen retrieval is also tested during optimization as this can also pro-
duce sufficient staining for some antibodies and antigens. Here, we
describe the key methods utilized in the protocols for IVD tissue
within our laboratory. It is our experience that these methods work
reliably for IVD tissues, heat retrieval can be problematic leading to
tissue section lifting and should only be used when necessary. It is
recommended to leave sections to dry for longer periods if heat
retrieval is required, steaming methods can be particular problematic
for disc tissue as they often lead to tissue swelling and dissociation
from slides.
5.1 | Heat antigen retrieval
Sections should be placed into a slide rack ensuring that 3 to 4 blank
slides are placed at either edge of the rack to reduce the effect of
bubbling on tissue sections (edges are affected to a greater extent and
F IGURE 2 Examples of immunostained formalin fixed paraffin embedded intervertebral disc tissue sections. A, Aquaporin 7 (Abcam
ab85907) cell membrane staining, canine nucleus pulposus (NP) tissue. B, Cytoplasmic Indian Hedgehog (Santa Cruz sc-1196) staining, human NP
tissue. C, Nuclear localisation of TonEBP (Abcam ab3446), human NP tissue. D, Pericellular and matrix staining of collagen type II (Abcam
ab34712), human NP tissue. E, Staining of aquaporin 6 (Abcam ab191061) indicating cartilaginous endplate (CEP) localisation, canine IVD
tissue. F, CD31 (Abcam ab28364) staining within human annulus fibrosus (AF) tissue indicating the presence of endothelial cell infiltration. G,
CCL3 (Abcam ab32609) staining within cell clusters, human NP tissue. H, Mouse IgG3, Kappa isotype control (Abcam ab18394), human NP
tissue. I, Rabbit IgG isotype control (Abcam ab37415), human NP tissue. A, B, E, F, G, H, I scale bar = 100 μm. C, D scale bar = 50 μm
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this can lead to tissue dissociation if slides with sections are placed in
the whole rack). Furthermore, if the rack is not full, extra microscope
slides should be added to all empty spaces to allow for even heat
distribution across all sections. The slide rack is then immersed in
400 mL antigen retrieval buffer (0.05 M Tris HCl, pH 9.5, preheated
to 60C), and irradiated for 5 minutes at 40% power in a Sanyo
800 W microwave oven (adjust time and power according to Watt
output of microwave). Sections are left to stand at room temperature
for 1 minute, before being irradiated for a further 5 minutes at 20%
power. Sections are left to stand for 15 minutes within the hot buffer
to cool.
5.2 | Enzyme antigen retrieval
Sections (in a slide rack) are placed in TBS containing 1% (w/v)
α-chymotrypsin and 0.1% CaCl2 (preheated to 37C) and incubated
for 30 minutes at 37C.
6 | ANTIGEN DETECTION
Following antigen retrieval, sections are washed three times in TBS
and then placed into humidified slide boxes. Nonspecific protein inter-
actions are blocked and secondary antibody host interactions are
TABLE 1 IHC Protocol for formalin fixed paraffin embedded IVD
tissue all suppliers are provided in Table 2
Step Action Timings
1 De-wax sections in sub-X 3 × 5 min
2 Rehydrate sections in 100% IMS/ethanol 3 × 5 min
3 Block endogenous peroxidases:
Submerge in 100% IMS/ethanol containing
3% (v/v) H2O2 and 0.06% (v/v) of
concentrated HCl
30 min
4 dH20 5 min
5 TBS (20 mM Tris, 150 mM NaCl, pH 7.5)
wash (on flat bed shaker)
3 × 5 min
6 Antigen retrieval:
None: proceed to step 8 -
Enzyme: Preheat 1× TBS buffer containing
0.1% (w/v) CaCl2 dihydrate and 0.01%
(w/v) α-chymotrypsin at 37C
30 min
Heat: Preheat buffer containing 0.05M Tris,
pH 9.5 to 60C. Submerge slides,
irradiate for 5 min at 40% power in
800 W microwave, leave to stand for
1 min, irradiate at 20% for another 5 min.
Leave to cool for 15 min at room
temperature.
26 min
7 TBS wash (on flat bed shaker) 3 × 5 min
8 Block nonspecific antibody-protein
interactions
1–2 hours
9 Remove excess blocking solution by
tapping slides on tissue paper.
-
10 Apply primary antibody or appropriate IgG
controls
Overnight
4C
Day 2
11 TBS wash (on flat bed shaker) 3 × 5 min
12 Apply conjugated secondary antibody
(Table 3)
30 min
13 TBS wash (on flat bed shaker) 3 × 5 min
14 Apply ABC elite reagent 30 min
15 TBS wash (on flat bed shaker) 3 × 5 min
16 Apply DAB solution 20 min
17 H2O wash (running cold tap water) 5 min
18 Counterstain nuclei with Mayer's
hematoxylin
1 min
19 “Blue” sections under running cold tap
water
5 min
20 Dehydrate sections in 100% IMS/ethanol 3 × 5 min
21 Clear sections in sub-X 3 × 5 min
22 Mount sections with coverslips using a
mounting medium compatible with
sub-X, for example, Pertex or DPX
-
TABLE 2 List of suggested reagents for use with IHC protocol
Reagent Supplier
Catalogue
number
10% neutral buffered formalin Leica
Biosystems
3800600
4% paraformaldehyde Fisher 15434389
EDTA Sigma Aldrich E9884
Sub-X Leica
Biosystems
3803670
IMS Fisher M/4450/17
H2O2 Sigma Aldrich H1009
Tris Fisher T/3710/60
NaCl Fisher S/3120/60
CaCl2 dihydrate Honeywell 223 506
α-chymotrypsin Sigma Aldrich 1002472729
Goat serum Sigma Aldrich G9203
Rabbit serum Sigma Aldrich R9133
Donkey serum Sigma Aldrich D9663
BSA Sigma Aldrich A2153
Primary and secondary
antibodies
See Table 3 See Table 3
VECTASTAIN Elite ABC HRP
reagent
Vector
Laboratories
PK-7100
DAB Sigma Aldrich D5905
Mayer's hematoxylin Leica
Biosystems
3801582E
Pertex Leica
Biosystems
3808707E
4 of 9 BINCH ET AL.
T
A
B
L
E
3
C
o
nd
it
io
ns
an
d
an
ti
bo
dy
di
lu
ti
o
ns
o
pt
im
iz
ed
us
in
g
th
e
im
m
un
o
hi
st
o
ch
em
is
tr
y
m
et
ho
d
o
ut
lin
ed
in
th
is
ar
ti
cl
e
R
ef
er
en
ce
T
ar
ge
t
an
ti
bo
dy
C
lo
na
lit
y
O
pt
im
al
di
lu
ti
o
n
A
nt
ig
en
re
tr
ie
va
l
Se
co
n
d
ar
y
an
ti
b
o
d
y
O
p
ti
m
al
d
ilu
ti
o
n
A
F
m
ar
ke
rs
[1
1
]a
C
o
lla
ge
n
ty
pa
e
I(
ab
9
0
3
9
5
)
M
o
us
e
m
o
no
cl
o
na
l
1
:2
0
0
E
nz
ym
e
R
ab
b
it
an
ti
m
o
u
se
(a
b
6
7
2
7
)
1
:5
0
0
[1
2
]b
C
o
lla
ge
n
ty
pe
I(
ab
3
4
7
1
0
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:2
0
0
E
nz
ym
e
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:5
0
0
B
on
e
m
ar
ke
rs
[1
2
]b
A
lk
al
in
e
P
ho
sp
ha
ta
se
(a
b1
0
8
3
3
7
)
R
ab
bi
t
m
o
no
cl
o
na
l
1
:2
0
0
H
ea
t
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:5
0
0
[1
2
]b
C
o
lla
ge
n
X
(a
b4
9
9
4
5
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:4
0
0
E
nz
ym
e
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:5
0
0
[1
2
]b
O
st
eo
ca
lc
in
(a
b1
3
4
2
0
)
M
o
us
e
m
o
no
cl
o
na
l
1
:4
0
0
E
nz
ym
e
R
ab
b
it
an
ti
m
o
u
se
(a
b
6
7
2
7
)
1
:5
0
0
[1
2
]b
O
st
eo
po
nt
in
(a
b6
9
4
9
8
)
M
o
us
e
m
o
no
cl
o
na
l
1
:2
0
0
N
o
ne
R
ab
b
it
an
ti
m
o
u
se
(a
b
6
7
2
7
)
1
:5
0
0
[1
2
]b
R
un
x2
(a
b7
6
9
5
6
)
M
o
us
e
M
o
no
cl
o
na
l
1
:2
0
0
N
o
ne
R
ab
b
it
an
ti
m
o
u
se
(a
b
6
7
2
7
)
1
:5
0
0
C
el
lc
yc
le
an
d
ap
op
to
si
s
[1
1
,1
3
]a
C
as
pa
se
3
(a
b1
3
8
4
7
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:4
0
0
N
o
ne
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:5
0
0
U
np
ub
lis
he
d
P
1
6
IN
K
4
a
(a
b1
0
8
3
4
9
)
R
ab
bi
t
m
o
no
cl
o
na
l
1
:1
0
0
N
o
ne
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:4
0
0
C
el
ls
ig
na
lin
g
[1
4
]
c-
ju
n
(a
b3
2
3
8
5
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:4
0
0
H
ea
t
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:3
0
0
[1
5
]c
IH
H
(S
an
ta
C
ru
z,
sc
-1
1
9
6
)
G
o
at
po
ly
cl
o
na
l
4
ug
/m
L
E
nz
ym
e
D
o
n
ke
y
an
ti
go
at
(a
b
6
8
8
4
)
1
:4
0
0
[9
]
N
F
kB
(a
b3
1
4
8
1
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:1
0
0
H
ea
t
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:3
0
0
[1
1
]
N
O
T
C
H
2
(a
b8
9
2
6
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:2
0
0
H
ea
t
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:4
0
0
[9
]
P
3
8
M
A
P
K
(a
b4
8
2
2
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:8
0
0
H
ea
t
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:3
0
0
[1
5
]c
P
T
C
H
(S
an
ta
C
ru
z,
sc
-6
1
4
9
)
G
o
at
po
ly
cl
o
na
l
1
:5
0
H
ea
t
D
o
n
ke
y
an
ti
go
at
(a
b
6
8
8
4
)
1
:3
0
0
[1
5
]c
P
T
H
rP
(S
an
ta
C
ru
z,
sc
-9
6
8
0
)
G
o
at
po
ly
cl
o
na
l
1
:2
5
H
ea
t
D
o
n
ke
y
an
ti
go
at
(a
b
6
8
8
4
)
1
:3
0
0
[1
5
]c
P
T
H
R
1
(S
an
ta
C
ru
z,
sc
-1
2
7
7
7
)
G
o
at
po
ly
cl
o
na
l
1
:2
0
H
ea
t
D
o
n
ke
y
an
ti
go
at
(a
b
6
8
8
4
)
1
:3
0
0
[1
5
]c
SM
O
(S
an
ta
C
ru
z,
sc
-6
3
6
6
)
G
o
at
po
ly
cl
o
na
l
1
:2
5
H
ea
t
D
o
n
ke
y
an
ti
go
at
(a
b
6
8
8
4
)
1
:3
0
0
C
yt
ok
in
es
an
d
ch
em
ok
in
es
[1
6
]
C
C
L2
(a
b9
6
6
9
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:5
0
0
H
ea
t
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:5
0
0
[1
7
]
C
C
L3
(a
b3
2
6
0
9
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:4
0
0
0
H
ea
t
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:5
0
0
[1
7
]
C
C
L4
(a
b9
6
7
5
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:2
0
0
0
H
ea
t
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:5
0
0
[1
6
]
C
C
L7
(a
b1
0
4
8
6
6
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:1
0
0
0
0
H
ea
t
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:5
0
0
[1
8
]
C
C
R
1
(a
b8
9
0
5
5
)
M
o
us
e
m
o
no
cl
o
na
l
1
:1
0
0
0
H
ea
t
R
ab
b
it
an
ti
m
o
u
se
(a
b
6
7
2
7
)
1
:4
0
0
[1
6
]
C
X
C
L8
(a
b7
7
4
7
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:1
0
0
H
ea
t
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:5
0
0
[1
8
]
C
X
C
R
1
(a
b6
0
2
5
4
)
M
o
us
e
m
o
no
cl
o
na
l
1
:2
0
0
0
H
ea
t
R
ab
b
it
an
ti
m
o
u
se
(a
b
6
7
2
7
)
1
:4
0
0
[1
8
]
C
X
C
R
2
(a
b2
4
9
6
3
)
M
o
us
e
m
o
no
cl
o
na
l
1
:5
0
0
H
ea
t
R
ab
b
it
an
ti
m
o
u
se
(a
b
6
7
2
7
)
1
:4
0
0
[1
1
]a
IL
-1
β
(a
b9
7
2
2
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:1
0
0
H
ea
t
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:5
0
0
[1
1
]a
IL
-1
R
I(
ab
1
0
0
2
7
8
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:1
0
0
E
nz
ym
e
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:5
0
0
[1
6
]
IL
-1
6
(a
b9
5
6
3
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:7
5
0
H
ea
t
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:5
0
0
(C
o
nt
in
u
es
)
BINCH ET AL. 5 of 9
T
A
B
L
E
3
(C
o
nt
in
ue
d)
R
ef
er
en
ce
T
ar
ge
t
an
ti
bo
dy
C
lo
na
lit
y
O
pt
im
al
di
lu
ti
o
n
A
nt
ig
en
re
tr
ie
va
l
Se
co
n
d
ar
y
an
ti
b
o
d
y
O
p
ti
m
al
d
ilu
ti
o
n
Im
m
un
e
m
ar
ke
rs
[1
8
]
C
D
4
(a
b5
1
3
1
2
)
M
o
us
e
m
o
no
cl
o
na
l
1
:5
0
0
H
ea
t
R
ab
b
it
an
ti
m
o
u
se
(a
b
6
7
2
7
)
1
:4
0
0
U
np
ub
lis
he
d
C
D
1
1
b
(a
b6
2
8
1
7
)
G
o
at
po
ly
cl
o
na
l
1
:8
0
0
N
o
ne
D
o
n
ke
y
an
ti
go
at
(a
b
6
8
8
4
)
1
:5
0
0
[1
2
]b
C
D
6
8
(a
b9
5
5
)
M
o
us
e
m
o
no
cl
o
na
l
1
:2
0
0
E
nz
ym
e
R
ab
b
it
an
ti
m
o
u
se
(a
b
6
7
2
7
)
1
:5
0
0
M
at
ri
x
re
m
od
el
in
g
[1
1
]a
A
D
A
M
T
S4
(a
b1
8
5
7
2
2
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:2
0
0
N
o
ne
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:5
0
0
[1
1
]a
M
M
P
3
(a
b5
3
0
1
5
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:4
0
0
E
nz
ym
e
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:5
0
0
[1
1
]a
M
M
P
1
3
(a
b3
9
0
1
2
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:2
0
0
H
ea
t
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:5
0
0
N
eu
ra
la
nd
va
sc
ul
ar
[1
9
]
N
F
2
0
0
(a
b8
2
2
5
9
)
M
o
us
e
m
o
no
cl
o
na
l
1
:4
0
0
H
ea
t
R
ab
b
it
an
ti
m
o
u
se
(a
b
6
7
2
7
)
1
:5
0
0
[1
9
]
P
G
P
9
.5
(a
b8
1
8
9
)
M
o
us
e
m
o
no
cl
o
na
l
1
:2
0
0
H
ea
t
R
ab
b
it
an
ti
m
o
u
se
(a
b
6
7
2
7
)
1
:5
0
0
[1
9
]
C
D
3
1
(a
b2
8
3
6
4
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:4
0
0
E
nz
ym
e
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:5
0
0
[2
0
]
Se
m
a3
C
(a
b1
3
5
8
4
2
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:2
0
0
N
o
ne
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:5
0
0
[2
0
]
Se
m
a3
D
(a
nt
ib
o
di
es
o
nl
in
e—
A
B
IN
1
3
8
6
6
3
9
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:2
0
0
E
nz
ym
e
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:5
0
0
[2
0
]
N
R
P
-1
(a
b8
1
3
2
1
)
R
ab
bi
t
m
o
no
cl
o
na
l
1
:2
0
0
H
ea
t
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:5
0
0
[2
0
]
N
R
P
-2
(a
b1
8
5
7
1
0
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:2
0
0
E
nz
ym
e
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:5
0
0
[2
0
]
P
le
xi
n
A
1
(a
b3
2
9
6
0
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:2
0
0
E
nz
ym
e
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:5
0
0
[2
1
]
Su
bs
ta
nc
e
P
(a
b1
0
3
5
3
)
M
o
us
e
m
o
no
cl
o
na
l
1
:5
0
0
N
o
ne
D
o
n
ke
y
an
ti
m
o
u
se
(A
le
xa
F
lu
o
r
4
8
8
)
1
:2
0
0
U
np
ub
lis
he
d
N
G
F
(a
b5
2
9
1
8
)
R
ab
bi
t
m
o
no
cl
o
na
l
1
:1
0
0
E
nz
ym
e
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:5
0
0
U
np
ub
lis
he
d
V
E
G
F
(a
b5
2
9
1
7
)
R
ab
bi
t
m
o
no
cl
o
na
l
1
:1
0
0
E
nz
ym
e
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:5
0
0
N
P
m
ar
ke
rs
[1
1
,1
3
]a
A
gg
re
ca
n
(a
b3
7
7
8
)
M
o
us
e
m
o
no
cl
o
na
l
1
:1
0
0
H
ea
t
R
ab
b
it
an
ti
m
o
u
se
(a
b
6
7
2
7
)
1
:5
0
0
[1
3
]a
C
ho
nd
ro
it
in
su
lp
ha
te
(a
b1
1
5
7
0
)
M
o
us
e
m
o
no
cl
o
na
l
1
:4
0
0
E
nz
ym
e
R
ab
b
it
an
ti
m
o
u
se
(a
b
6
7
2
7
)
1
:5
0
0
[1
1
]a
C
o
lla
ge
n
ty
pe
II
(a
b3
4
7
1
2
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:2
0
0
E
nz
ym
e
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:5
0
0
[1
3
]a
C
o
lla
ge
n
ty
pe
II
(a
b3
0
9
2
)
M
o
us
e
m
o
no
cl
o
na
l
1
:2
0
0
E
nz
ym
e
R
ab
b
it
an
ti
m
o
u
se
(a
b
6
7
2
7
)
1
:5
0
0
[1
0
,2
1
]a
F
O
X
F
1
(a
b2
3
1
9
4
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:1
0
0
H
ea
t
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:5
0
0
[1
1
]a
H
IF
1
α
(a
b1
6
0
6
6
)
M
o
us
e
m
o
no
cl
o
na
l
1
:1
0
0
N
o
ne
R
ab
b
it
an
ti
m
o
u
se
(a
b
6
7
2
7
)
1
:5
0
0
[2
2
]
K
R
T
-1
9
(a
b7
7
5
4
)
M
o
us
e
m
o
no
cl
o
na
l
1
:4
0
0
N
o
ne
R
ab
b
it
an
ti
m
o
u
se
(a
b
6
7
2
7
)
1
:5
0
0
[2
2
]
LA
M
-5
(a
b7
8
2
8
6
)
M
o
us
e
m
o
no
cl
o
na
l
1
:8
0
0
E
nz
ym
e
R
ab
b
it
an
ti
m
o
u
se
(a
b
6
7
2
7
)
1
:5
0
0
[1
0
,2
1
]a
P
A
X
1
(a
b2
0
3
0
6
5
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:4
0
0
E
nz
ym
e
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:5
0
0
O
sm
ot
ic
re
gu
la
ti
on
[2
3
]c
A
Q
P
0
(a
b1
3
4
6
9
5
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:2
0
0
E
nz
ym
e
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:5
0
0
[2
3
,2
4
]c
A
Q
P
1
(a
b1
5
0
8
0
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:4
0
0
N
o
ne
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:5
0
0
6 of 9 BINCH ET AL.
T
A
B
L
E
3
(C
o
nt
in
ue
d)
R
ef
er
en
ce
T
ar
ge
t
an
ti
bo
dy
C
lo
na
lit
y
O
pt
im
al
di
lu
ti
o
n
A
nt
ig
en
re
tr
ie
va
l
Se
co
n
d
ar
y
an
ti
b
o
d
y
O
p
ti
m
al
d
ilu
ti
o
n
[2
3
]c
A
Q
P
2
(a
b8
5
8
7
6
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:4
0
0
N
o
ne
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:5
0
0
[2
3
]c
A
Q
P
3
(a
b1
2
5
2
1
9
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:1
6
0
0
E
nz
ym
e
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:5
0
0
[2
3
]c
A
Q
P
4
(a
b9
5
1
2
)
M
o
us
e
m
o
no
cl
o
na
l
1
:2
0
0
E
nz
ym
e
R
ab
b
it
an
ti
m
o
u
se
(a
b
7
0
7
4
)
1
:5
0
0
[2
3
]c
[2
4
]
A
Q
P
5
(a
b9
2
3
2
0
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:1
0
0
H
ea
t
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:5
0
0
[2
3
]c
A
Q
P
6
(a
b1
9
1
0
6
1
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:2
0
0
E
nz
ym
e
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:5
0
0
[2
3
]c
A
Q
P
7
(a
b8
5
9
0
7
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:1
0
0
E
nz
ym
e
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:5
0
0
[2
3
]c
A
Q
P
9
(a
b8
5
9
1
0
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:4
0
0
E
nz
ym
e
G
o
at
an
ti
ra
b
b
it
(a
b
6
7
2
0
)
1
:5
0
0
[2
5
]
T
o
nE
B
P
(a
b3
4
4
6
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:1
0
0
H
ea
t
G
o
at
an
ti
ra
b
b
it
(a
b
9
7
0
4
9
)
1
:5
0
0
C
a2
+
ch
an
ne
ls
U
np
ub
lis
he
d
T
R
P
V
1
(a
b3
4
8
7
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:1
0
0
E
nz
ym
e
G
o
at
an
ti
ra
b
b
it
(a
b
9
7
0
4
9
)
1
:5
0
0
U
np
ub
lis
he
d
T
R
P
V
4
(a
b9
4
8
6
8
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:2
0
0
E
nz
ym
e
G
o
at
an
ti
ra
b
b
it
(a
b
9
7
0
4
9
)
1
:5
0
0
La
ct
at
e
tr
an
sp
or
t
[2
6
]
M
C
T
1
(S
an
ta
C
ru
z,
sc
-5
0
3
2
4
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:2
0
H
ea
t
G
o
at
an
ti
ra
b
b
it
(a
b
9
7
0
4
9
)
1
:5
0
0
[2
6
]
M
C
T
4
(S
an
ta
C
ru
z,
sc
-5
0
3
2
9
)
R
ab
bi
t
po
ly
cl
o
na
l
1
:1
0
H
ea
t
G
o
at
an
ti
ra
b
b
it
(a
b
9
7
0
4
9
)
1
:5
0
0
[2
6
]
C
D
1
4
7
(S
an
ta
C
ru
z,
sc
-9
7
5
4
)
G
o
at
po
ly
cl
o
na
l
1
:1
0
H
ea
t
D
o
n
ke
y
an
ti
go
at
(a
b
6
8
8
4
)
1
:5
0
0
N
ot
e:
A
ll
an
ti
bo
di
es
o
pt
im
iz
ed
fo
r
us
e
o
n
fo
rm
al
in
fi
xe
d
pa
ra
ff
in
em
be
dd
ed
(F
F
P
E
)h
um
an
in
te
rv
er
te
br
al
di
sc
(IV
D
)t
is
su
e.
a
P
ub
lic
at
io
ns
re
fe
re
nc
ed
re
po
rt
th
es
e
an
ti
bo
di
es
in
o
pt
im
iz
ed
fo
r
us
e
o
n
hu
m
an
m
es
en
ch
ym
al
st
em
ce
lls
em
be
dd
ed
w
it
hi
n
hy
dr
o
ge
l.
b
O
pt
im
iz
ed
fo
r
us
e
o
n
m
ur
in
e
bo
ne
ti
ss
ue
.
c A
ls
o
o
pt
im
iz
ed
fo
r
us
e
o
n
ca
ni
ne
IV
D
ti
ss
ue
.A
ll
an
ti
bo
di
es
su
pp
lie
d
by
A
bc
am
un
le
ss
st
at
ed
o
th
er
w
is
e.
BINCH ET AL. 7 of 9
neutralized by the application of 200 μL 1% (w/v) BSA in 75% v/v
TBS and 25% (v/v) normal serum (matched to the species which the
secondary antibody was raised in) and incubated for 1 to 2 hours at
room temperature. Optimum antibody concentrations are pre-
determined by optimizations whereby a range of concentrations and
antigen retrieval methods are tested for optimal staining (a list of
preoptimized antibodies is documented in Table 3). Primary antibodies
are diluted in 1% (w/v) BSA in TBS and sections incubated overnight at
4C to enable binding of antibody to antigens. Parallel sections should
be incubated in IgG controls (Figure 2B) to ensure primary antibodies
are not binding nonspecifically. It is important that tissue samples do not
dry out at any point, if drying occurs this can lead to nonspecific staining
which often appears as high intensity staining around the edge of the
tissue.
6.1 | Detection of bound primary antibody
All sections are washed three times in TBS on an orbital shaker, before
biotinylated secondary antibody is applied for 30 minutes at room tem-
perature. Antibody dilutions are performed in 1% (w/v) BSA in TBS.
6.2 | Visualization of bound secondary antibody
Following secondary antibody application, sections are washed three
times in TBS before 2 to 3 drops of ABC Elite Reagent (Vector Labora-
tories, UK) is applied for 30 minutes at room temperature. The addi-
tion of avidin-biotin-complex (ABC) reagent (HRP labeled streptavidin
solution) allows the formation of a “streptavidin-biotin” complex with
the secondary antibody. Sections are washed three times prior to
application of 200 μL per section of 0.08% (v/v) hydrogen peroxide in
0.65 mg/mL DAB in TBS for 20 minutes. The enzymatic reaction
between DAB and HRP forms a permanent dark brown precipitate all-
owing visualization of bound antibodies. Sections are washed in dH2O
for 5 minutes prior to immersion in Mayer's Hematoxylin (Leica, UK)
for 1 minute and blued under running tap water for 5 minutes.
7 | MOUNTING OF SECTIONS
Sections are dehydrated, cleared and mounted in Pertex (Leica, UK).
8 | EVALUATION OF IHC
In addition to utilizing IHC to determine localisation of proteins of
interest, semiquantitative analysis can be performed. For each primary
antibody, 200 cells within each region of interest (eg, nucleus
pulposus/annulus fibrosis/cartilaginous endplate) are counted. It is
also possible to analyze cell clusters and single cells separately
depending on your hypothesis. To ensure avoidance of selection bias
for areas of staining, the first field of view of the tissue of interest
should be the start point of analysis. Analysis of that tissue area
should then be performed in a raster fashion to ensure no selection or
double counting. Cells are counted as immunopositive (brown) or
immunonegative (Purple nuclei counter stain only) (Figure 2) and the
percentage of immunopositive cells can be calculated and plotted. As
percentage data is utilized for quantification, data is not normally dis-
tributed and thus means and standard errors should not be used.
Graphical representation should show all data points or utilize a box
and whisker plot or other graph suitable for nonparametric data.
For the quantification of extracellular proteins such as extracellu-
lar matrix markers cellular immunopositive staining is still useful as this
indicates current cellular production of these proteins (as long as the
antigen detects the intracellular form). This can be complemented by
percentage area of immunopositivity which can be quantified using
ImageJ software. The use of image intensity for IHC analysis should
be avoided for ABC/DAB methodology as the signal is an amplified
signal and intensity cannot be directly related to quantity of protein.
8.1 | Automated IHC analysis
While there are a number of automatic image analysis systems which
enable automatic IHC quantification for tissues, which is particularly used
in the cancer fields.8 These systems can be problematic for disc tissues.
Disc tissues contain few cells (4 × 106 cells/cm3) in the NP,9,10 which
means either large numbers of images must be captured and analyzed, or
full slide analysis is required. For the majority of laboratories who do not
have facilities for rapid reliable full slide image capture it is often more
time and cost effective to manually quantify immunopositivity down the
microscope. Furthermore, it is important to accurately identify tissue type
of interest (eg, NP, AF, and CEP) during analysis and this can be just as
time consuming to “label” tissue areas within image capturing software.
9 | STATISTICAL ANALYSIS
As data is not normally distributed (percentage data) data should be ana-
lyzed using nonparametric testing dependant on the groups and hypoth-
esis being tested. For example, where investigating immunopositivity
between grades of histological degeneration if more than two groups
are analyzed a Kruskal-Wallis test with appropriate posthoc analysis can
be performed when a significant difference is seen between study
groups. Linear regression analysis can be used to observe correlations
between for instance, percentage immunopositivity and grade of degen-
eration, and correlation between target molecules or age.
10 | CONCLUSIONS
IHC is a reliable technique which can provide key insights into the
expression and localization of proteins within cells and tissues. While
semiquantifiable it can provide key indications of changes in cellular
expression of proteins during disc development, disease and
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regenerative strategies. IHC can also be an essential tool to help char-
acterize cells and garner an understanding of their behavior in their
natural state. However, it is essential to ensure samples are processed
appropriately, thin flat sections are prepared, and antibodies selected
and optimized to ensure complete antigen retrieval and avoiding non-
specific background staining, supported with appropriate controls.
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